193 related articles for article (PubMed ID: 30911439)
1. Targeting ELTD1, an angiogenesis marker for glioblastoma (GBM), also affects VEGFR2: molecular-targeted MRI assessment.
Ziegler J; Zalles M; Smith N; Saunders D; Lerner M; Fung KM; Patel M; Wren JD; Lupu F; Battiste J; Towner RA
Am J Nucl Med Mol Imaging; 2019; 9(1):93-109. PubMed ID: 30911439
[TBL] [Abstract][Full Text] [Related]
2. ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models.
Ziegler J; Pody R; Coutinho de Souza P; Evans B; Saunders D; Smith N; Mallory S; Njoku C; Dong Y; Chen H; Dong J; Lerner M; Mian O; Tummala S; Battiste J; Fung KM; Wren JD; Towner RA
Neuro Oncol; 2017 Feb; 19(2):175-185. PubMed ID: 27416955
[TBL] [Abstract][Full Text] [Related]
3. Assessment of an scFv Antibody Fragment Against ELTD1 in a G55 Glioblastoma Xenograft Model.
Zalles M; Smith N; Saunders D; Saran T; Thomas L; Gulej R; Lerner M; Fung KM; Chung J; Hwang K; Jin J; Battiste J; Towner RA
Transl Oncol; 2020 Mar; 13(3):100737. PubMed ID: 32208341
[TBL] [Abstract][Full Text] [Related]
4. Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model.
Zalles M; Smith N; Ziegler J; Saunders D; Remerowski S; Thomas L; Gulej R; Mamedova N; Lerner M; Fung KM; Chung J; Hwang K; Jin J; Wiley G; Brown C; Battiste J; Wren JD; Towner RA
J Cell Mol Med; 2020 Jan; 24(2):1738-1749. PubMed ID: 31863639
[TBL] [Abstract][Full Text] [Related]
5. A tale of two multi-focal therapies for glioblastoma: An antibody targeting ELTD1 and nitrone-based OKN-007.
Zalles M; Smith N; Saunders D; Lerner M; Fung KM; Battiste J; Towner RA
J Cell Mol Med; 2022 Jan; 26(2):570-582. PubMed ID: 34910361
[TBL] [Abstract][Full Text] [Related]
6. ELTD1 as a biomarker for multiple sclerosis: Pre-clinical molecular-targeted studies in a mouse experimental autoimmune encephalomyelitis model.
Towner RA; Smith N; Zalles M; Morris S; Toliver M; Saunders D; Lerner M; Kumar G; Axtell RC
Mult Scler Relat Disord; 2021 Apr; 49():102786. PubMed ID: 33517175
[TBL] [Abstract][Full Text] [Related]
7. ELTD1 as a multi-focal target for malignant gliomas: preclinical studies.
Zalles M; Smith N; Saunders D; Guzman M; Lerner M; Fung KM; Babu A; Battiste J; Chung J; Hwang K; Jin J; Towner RA
Neurooncol Adv; 2021; 3(1):vdab132. PubMed ID: 34704036
[TBL] [Abstract][Full Text] [Related]
8. ELTD1, a potential new biomarker for gliomas.
Towner RA; Jensen RL; Colman H; Vaillant B; Smith N; Casteel R; Saunders D; Gillespie DL; Silasi-Mansat R; Lupu F; Giles CB; Wren JD
Neurosurgery; 2013 Jan; 72(1):77-90; discussion 91. PubMed ID: 23096411
[TBL] [Abstract][Full Text] [Related]
9. ELTD1 Review: New Regulator of Angiogenesis in Glioma.
Buzatu I; Tache DE; Manea Carneluti EV; Zlatian O
Curr Health Sci J; 2023; 49(4):495-502. PubMed ID: 38559823
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor, latrophilin, and seven transmembrane domain-containing protein 1 marker, a novel angiogenesis marker.
Serban F; Artene SA; Georgescu AM; Purcaru SO; Tache DE; Alexandru O; Dricu A
Onco Targets Ther; 2015; 8():3767-74. PubMed ID: 26719704
[TBL] [Abstract][Full Text] [Related]
11. Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model.
Mitran B; Güler R; Roche FP; Lindström E; Selvaraju RK; Fleetwood F; Rinne SS; Claesson-Welsh L; Tolmachev V; Ståhl S; Orlova A; Löfblom J
Theranostics; 2018; 8(16):4462-4476. PubMed ID: 30214632
[TBL] [Abstract][Full Text] [Related]
12. AG488 as a therapy against gliomas.
Ziegler J; Bastian A; Lerner M; Bailey-Downs L; Saunders D; Smith N; Sutton J; Battiste JD; Ihnat MA; Gangjee A; Towner RA
Oncotarget; 2017 Sep; 8(42):71833-71844. PubMed ID: 29069750
[TBL] [Abstract][Full Text] [Related]
13. Silencing of epidermal growth factor, latrophilin and seven transmembrane domain-containing protein 1 (ELTD1) via siRNA-induced cell death in glioblastoma.
Serban F; Daianu O; Tataranu LG; Artene SA; Emami G; Georgescu AM; Alexandru O; Purcaru SO; Tache DE; Danciulescu MM; Sfredel V; Dricu A
J Immunoassay Immunochem; 2017; 38(1):21-33. PubMed ID: 27379831
[TBL] [Abstract][Full Text] [Related]
14. Magnetic Resonance Elastography reveals effects of anti-angiogenic glioblastoma treatment on tumor stiffness and captures progression in an orthotopic mouse model.
Schregel K; Nowicki MO; Palotai M; Nazari N; Zane R; Sinkus R; Lawler SE; Patz S
Cancer Imaging; 2020 May; 20(1):35. PubMed ID: 32398076
[TBL] [Abstract][Full Text] [Related]
15. A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.
Towner RA; Ihnat M; Saunders D; Bastian A; Smith N; Pavana RK; Gangjee A
BMC Cancer; 2015 Jul; 15():522. PubMed ID: 26177924
[TBL] [Abstract][Full Text] [Related]
16. ELTD1 deletion reduces vascular abnormality and improves T-cell recruitment after PD-1 blockade in glioma.
Huang H; Georganaki M; Conze LL; Laviña B; van Hooren L; Vemuri K; van de Walle T; Ramachandran M; Zhang L; Pontén F; Bergqvist M; Smits A; Betsholtz C; Dejana E; Magnusson PU; He L; Lugano R; Dimberg A
Neuro Oncol; 2022 Mar; 24(3):398-411. PubMed ID: 34347079
[TBL] [Abstract][Full Text] [Related]
17. Molecular MRI differentiation of VEGF receptor-2 levels in C6 and RG2 glioma models.
He T; Smith N; Saunders D; Pittman BP; Lerner M; Lightfoot S; Silasi-Mansat R; Lupu F; Towner RA
Am J Nucl Med Mol Imaging; 2013; 3(4):300-11. PubMed ID: 23901356
[TBL] [Abstract][Full Text] [Related]
18. Novel approaches to combat chemoresistance against glioblastomas.
Towner RA; Zalles M; Saunders D; Smith N
Cancer Drug Resist; 2020; 3(4):686-698. PubMed ID: 35582224
[TBL] [Abstract][Full Text] [Related]
19. Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo.
Szabo E; Schneider H; Seystahl K; Rushing EJ; Herting F; Weidner KM; Weller M
Neuro Oncol; 2016 Sep; 18(9):1242-52. PubMed ID: 27009237
[TBL] [Abstract][Full Text] [Related]
20. A review of ELTD1, a pro-angiogenic adhesion GPCR.
Favara DM; Banham AH; Harris AL
Biochem Soc Trans; 2014 Dec; 42(6):1658-64. PubMed ID: 25399586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]